Identifies new GPR17 antagonists with high potency in neurodegenerative contexts, suggesting therapeutic potential.
High Resolution Image Download MS PowerPoint Slide GPR17, a G protein-coupled receptor (GPCR) involved in neurodegenerative and repair processes, represents a promising therapeutic target. In this study, an integrated strategy combining structure-guided prioritization of a focused nucleotide-inspired library with experimental assays was employed to identify new GPR17 antagonists. A library of 130 nucleosides, nucleotides, and related derivatives was prioritized by molecular docking, leading to the selection of four candidates (8-methylamino inosinic acid and N 2 - n -octyl-, N 2 -butyryl- and N 2 -undecanoyl-2′,3′- O -isopropylideneguanylic acid). These compounds were synthesized and evaluated using Grating-Coupled Interferometry (GCI), which confirmed nanomolar affinities comparable to the reference antagonist Cangrelor. Functional [ 35 S]GTPγS binding assays demonstrated that all tested compounds act as GPR17 antagonists, with N 2 - n -octyl-, N 2 -butyryl- and N 2 -undecanoyl-2′,3′- O -isopropylideneguanylic acids showing the highest potency. This integrated approach, combining computational modeling, targeted synthesis, and experimental validation, provides a solid foundation for the rational design of selective GPR17 ligands and paves the way for future optimization efforts aimed at therapeutic applications in neurodegenerative disorders and neural tissue repair.
No takes yet. Share an insight, caveat, or question.
Rabuffetti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: